@melua. Good questions. Management is exploring non-dilutionary...

@melua. Good questions.

Management is exploring non-dilutionary alternatives for funding to carry them through till they are CF+. To date, they have been very successful at tapping concessional loans from US government and have deferred repayments on their loan from Touchstone. We'll see how they go in this regard, but they have already indicated the need for further $$$ to fund an expansion of their CFOAM manufacturing facility.

To your other question, the USN deal ann. today is a relatively small order (the exact quantum may be hidden behind a NDA), but this ann. is intended to signal the possibility of up to $100M in gross revenue over the next 3-5 years if the USN deal proceeds. (If there's no NDA, CFO may attract a please qualify from the ASX - we'll see).

If the USN sea-based trial in early 2019 is a success and the USN deal goes ahead, CFO will have the means to massively ramp up its manufacturing capacity, in line with its strategic plans, thereby providing production guarantees for existing and prospective customers (the company has identified this as the key issue holding back new sales and revenues).

As with other ASX microcap tech plays, there's still a long way to go... but this is a significant step forward in de-risking the company for investors and strengthening its prospects in the medium/longer-term. (NB CFO already counts major US aerospace companies among its customers, so there is industry recognition of the quality of their offering. What they have needed is volume to justify an expansion of their production facilities...). GLTAH R-7